World's first lung cancer vaccine trials launched globally

Trials for the world's first mRNA lung cancer vaccine, BNT116, have begun across seven countries, including the UK, US, and Germany. The vaccine targets non-small cell lung cancer (NSCLC), responsible for 1.8 million deaths annually. Approximately 130 patients will participate, with the first UK patient receiving the jab this week. The trial aims to enhance immune response while minimizing damage to healthy cells.